Triple-drug combination extending life for women with aggressive HR+/HER2− breast cancer
Triple-drug combination extending life for women with aggressive HR+/HER2− breast cancer
In late May 2025 a major funding round highlights how investors are backing clinical-stage pipelines together with AI …
FDA’s Oncologic Drugs Advisory Committee (ODAC) critiques a major lymphoma trial for having too few U.S. participants, warning …
Combination therapy delivers promising efficacy and manageable safety in PD-1 refractory head and neck squamous cell carcinoma
Oral brain-penetrant NLRP3 inhibitor and new collaborations place BioAge at center of metabolic aging drug development
Trial halt and valuation collapse trigger major workforce reduction at fibrosis-focused biotech
Dual clinical studies reveal statistically meaningful benefits for patients with MSA, highlighting a leap forward for disease-modifying treatment …
New research unveiled at the American Association for Cancer Research meeting points to promising treatments for head and …
Zydus’ experimental therapy demonstrates significant improvements in liver function and patient outcomes, signaling new hope in a disease …
New safety and efficacy evidence supports expanded use of mavacamten in oHCM patients
Already a subscriber? Log in